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Introduction. Patients with symptoms 
suggestive of acute coronary syndrome 
(ACS) have various medical backgrounds 
and different stages of underlying coro-
nary disease. Hence, patients entering 
the emergency room (ER) with ACS sug-
gestive symptoms, present a challenge to 
emergency physicians. We hypothesized 
that a point-of-care test (POCT) for mul-
tiple cardiac biomarkers can be used as a 
prognostic tool for predicting severity and 
hospital mortality in acute myocardial in-
farction (AMI) patients.
Methods . We conducted a retrospective 
analysis of all patients who presented to 
the ER of a university urban hospital with 
chest pain, chest discomfort and short-
ness of breath of potential cardiovascular 
origin during a  3-year period. Biomarkers 
from the POCT and coronary angiography 
(CAG) results were used for diagnosis. Se-
verity was evaluated based on involvement 
and status of major coronary arteries, ejec-
tion fraction and in-hospital mortality. 
Results. Out of 1336 patients, 329 patients 
were diagnosed with AMI. Risk of major 
coronary artery occlusion was increased 
with an increased number of positive 
POCT findings. The percentage of patients 
with severe left ventricular dysfunction 
was higher in the group with 2 or 3 posi-
tive POCTs than 0 or 1. As the number of 
positive POCTs increased from 1 to 3, our 
results showed an increment in the per-
centage of in-hospital mortality
Conclusions. This study identified the pos-
sibility of a POCT as a prognostic tool. The 
POCT is easy to use by the bedside and can 
be checked relatively quickly? in a short 
period of time. If the POCT result is used 
to predict the prognosis in ACS patients, 
emergency physicians may approach pa-
tients with more caution.
Key words: chest pain, shortness of breath, 
acute myocardial infarction, in-hospital 
mortality 
INTRODUCTION    
 
Chest discomfort, pain and tightness with 
or without shortness of breath are always 
challenging symptoms for emergency phy-
sicians. Chest pain is one of the common-
est reasons for admission to the emergency 
room (ER). Common causes include stable 
angina, gastrointestinal disease, panic dis-
order, viral infection and musculoskeletal 
pain. The most serious causes are acute 
coronary syndrome (ACS), heart failure 
(HF) and thromboembolic events (TE). 
(1-3) Patients with symptoms suggestive 
of ACS have various medical backgrounds 
and different stages of underlying coro-
nary disease. Hence, patients entering the 
ER with ACS suggestive symptoms pre-
sent a diagnostic, prognostic and thera-
peutic challenge. ACS is divided, based on 
electrocardiogram (ECG) findings, into 
ST-segment elevation myocardial infarc-
tion (STEMI), non-ST-segment elevation 
myocardial infarction (NSTEMI) and un-
stable angina (UA). The disruption of an 
atherosclerotic plaque and thrombus for-
mation, causing partial or complete occlu-
sion of the infarct-related artery or distal 
embolization in the coronary vessel, are 
key events of ACS development. (4) Many 
biomarkers are available for the diagnosis 
of ACS and utility of biomarkers may be 
used for diagnosis, prognosis and selection 
of appropriate treatment. (5,6) Also, the 
utility of biomarkers can be used essen-
tially in risk stratification and diagnosis of 
acute myocardial infarction (AMI). (7,8) 
The most frequently used biomarkers are 
cardiac troponin T (cTnT) or cardiac tro-
ponin I (cTnI), brain natriuretic peptide 
(BNP) and D-dimer. (9) Additionally, cre-
atine kinase MB (CK-MB) and myoglobin 
are used as adjuvant tests. CTnI or cTnT 
is a highly specific and sensitive protein 
for the diagnosis of ACS. (10,11) Elevated 
troponin due to myocardial necrosis is 
probably the result of a complex, throm-
botic coronary lesion. (12,13) BNP iden-
tifies cardiac origin dyspnea and excludes 
heart failure (HF) in an ACS suspected 
patient. (14) Cardiac ventricles’ increased 
wall tension leads to release of BNP and 
the N-terminal part of its pre-hormone 
(NT-proBNP) from myocytes. (15) Al-
though BNP and NT-pro-BNP are widely 
used for the diagnosis of HF, many studies 
show an elevated level of BNP in the early 
stage of ACS. It has also been shown to 
be a strong indicator of mortality in ACS 
patients. (16,17) D-dimer is a degradation 
product of cross-linked fibrin and it is el-
evated in the presence of an acute clot due 
to simultaneous activation of coagulation 
and fibrinolysis. (18-20) Plasma D-dimer 
is useful for the exclusion of pulmonary 
embolism (PE) and deep vein thrombo-
sis (DVT). (21) Its specificity is usually 
low given that it is elevated in numerous 
non-thrombotic situations. (22) With a 
high sensitivity and high negative predic-
tive value, D-dimer functioned as a great 
screening tool for suspected PE. However, 
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D-dimer was often elevated in the absence 
of PE. It had a low specificity and poor 
positive predictive value. (22-28)
In this study, we hypothesized that the 
point-of-care test (POCT) for multiple 
cardiac biomarkers can be used as a prog-
nostic tool for estimating the severity and 
in-hospital mortality of AMI patients. In 
other words, the occlusion of the left main 
coronary artery, number of involved coro-
nary arteries and the ejection fraction (EF) 
of the left ventricle (LV), may be used as 
factors that reflect the severity of AMI. 
Our aim was to analyze the utility of the 
POCT of multiple cardiac biomarkers for 
risk stratification in the setting of an emer-
gency department.
METHODS
We conducted a retrospective analysis of 
all patients who presented to the ER of an 
urban university hospital with chest pain, 
chest discomfort and shortness of breath, 
of potential cardiovascular origin, during 
a 3-year period (January 2013 to Decem-
ber 2015). We reviewed the electronic re-
cords of all patients. Patients  diagnosed 
with AMI, based on the International 
Classification of Diseases, tenth Revision 
(ICD-10) code 29, POCT multiple cardiac 
biomarkers findings and coronary angiog-
raphy (CAG) results,, were included in our 
study. General demographics, initial vital 
signs, POCT results, ejection fractions, 
CAG results and in-hospital mortalities 
were collected from the sample. Severity 
was evaluated based on involvement of the 
left main coronary artery, number of in-
volved coronary arteries, ejection fraction 
from a 2 dimensional cardio-echogram 
and in-hospital mortality. Shortness of 
Breath (SOB) kit (Alere TM Triage® Meter-
Pro, Allere Inc. San Diego, CA. USA) was 
used for biomarker testing. Five biomark-
ers, previously mentioned, were assessed 
using fluorescence immunoassay by plac-
ing 0.5mg of patient’s whole blood onto the 
kit.   The time required for the kit to ana-
lyze the blood sample is about 10~15 min-
utes. Standard values for each biomarker 
are set to the manufacturer’s normal rang-
es and they are: CK-MB 0.0 – 4.3 ng/mL, 
Myoglobin 0.0 – 107 ng/mL, Tnl < 0.05 ng/
mL, BNP 0.0 – 100 pg/mL, D-dimer 0.0-
400 ng/mL respectively.  If measurement of 
Tnl reaches between 0.05 – 0.39 ng/mL, it 
is considered slightly abnormal and if it is 
over 0.4 ng/mL, it is definitely abnormal, 
according to the manufacture.
After reviewing patients’ final diagnosis, 
AMI, heart failure and pulmonary embo-
lism were defined as representing acute 
coronary vascular diseases. AMI is defined 
as more than one of following: elevation of 
serum CK-MB or Troponin during hospi-
tal stay, ischemic change in electrocardio-
gram (EKG), newly found impaired wall 
motion in 2-dimensional echocardiogram 
(2-D Echo) and confirmed coronary artery 
occlusion in CAG. Patients with more than 
70% stenosis in one of the three major ar-
teries, including the left anterior descend-
ing (LAD), left circumflex (LCX) and right 
coronary artery (RCA) or in their first-
order branches were eligible for percuta-
neous coronary intervention (PCI). There-
fore, occlusion of more than 70% of major 
arteries was considered to be involved. 
Clinical symptoms suspicious of heart 
failure and decreased ejection fraction on 
2-D Echo were needed to diagnose heart 
failure. Ejection fraction (EF) above 55% 
was considered normal, between 45~54% 
was considered moderate and below 45% 
was considered severe. Pulmonary em-
bolism was diagnosed when an embolus 
was confirmed on 64 channel computed 
tomography (CT). In-hospital-mortality 
was defined as a final prognostic index and 
it was collected for each acute coronary 
vascular diseases. Chi-square test was used 
to analyze the relationship between initial 
elevation of Tnl, BNP and D-dimer and 
the prognosis of each disease in the group 
of patients who were diagnosed with AMI 
and heart failure. In the pulmonary em-
bolism group, the difference in mortality, 
depending on initial elevation of Tnl and 
BNP, was analyzed in the same manner. 
Initial measurement of Tnl was subdivided 
into < 0.05ng/mL, 0.05 – 0.39 ng/mL, and 
> 0.40 ng/mL and the effect of the result 
on prognosis was analyzed. All statistical 
analyses were conducted using SPSS 10.29 
(IBM Inc. Armonk, NY).
This study was approved by the Institu-
tional Review Board (IRB) of the Korea 
University Guro Hospital.
Approval number is KUGH16262-001
RESULTS 
A total of 1336 patients were tested with 
POCT for multiple cardiac biomarkers; 
329 patients were diagnosed with AMI. 
Two patients died before enrollment into 
the study due to cardiac arrest at presen-
tation. Among the 329 patients, CAG was 
done on 280 patients. Among the CAG 
group, 17 patients died and 263 were dis-
charged alive (figure 1).
General characteristics and information 
about the study group are shown in Table 
1. Average age was 58 ± 16 years and male 
patients were more common than female 
(64.3% vs. 35.7%). Chest pain was the most 
common symptom and angina pectoris 
(including other forms of angina pectoris) 
was the most common final diagnosis, fol-
lowed by AMI and unstable angina.
17 patients died within 30 days of CAG, 
and 263 patients were discharged alive. 
Analysis of the expired and survival group, 
showed expired patients to be older (72±8 
vs. 58±13 years, P<0.001) and have a lower 
systolic blood pressure (103±24 vs. 132±26 
mmHg, P<0.001). Initial biomarker levels, 
Tn-I (16.0(0-30) vs. 1.4(0-3.0) ng/mL [CI], 
P<0.001), BNP (532(125-1180) vs. 31(5-
215) pg/mL [CI], P<0.001) and D-dimer 
(567(259-1535) vs. 119(100-393) ng/mL 
[CI], P<0.001) were higher in the expired 
group compared to the survival group. On 
CAG findings, mortality was higher when 
more coronary arteries were occluded 
(P=0.005) (table 2).  
The risk of left main coronary artery occlu-
sion increased with the number of positive 
POCTs. When three POCT were positive, 
the percentage of involvement of the left 
Figure 2. Involvement of left main 
coronary artery in relation to number of 
positive POCT.
Figure 1. Selection of study population
ACS, Acute coronary syndrome; AMI, 
Acute myocardial infarction; CAG, Coro-
nary angiography; POCT, Point-of-care 
test. 
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main coronary artery was increased 10 
fold (1.6% to 16.7%, P<0.001). The risk in-
creased more than 3 times with 2 positive 
POCT compared to none (1.6% to 5.9%, 
P=0.005) (figure 2).
The risk of 3 vessel coronary artery disease 
in patients with 2 and/or 3 positive POCT 
vs patients with 0 and/or 1 positive POCT 
was 35.3% and/or 30% vs. 14.7% and/or 
13.2%, P=0.005, respectively (figure 3).
To verify the severity of left ventricu-
lar dysfunction, we sought to compare 
the percentage of patients with EF below 
45% with the number of positive POCTs. 
The percentage of patients with severe left 
ventricular dysfunction was higher in 2 or 
3 positive POCTs than 0 or 1 (36.5% or 
46.2% vs. 9.9% or 46.2%, P<0.001) (figure 
4).   
In-hospital death was not noticed in the 
group with no positive POCT. However, as 
the number of positive POCTs increased 
from1 to 3, our results showed an incre-
ment in the percentage of in-hospital mor-
tality (7.2%, 10.4%, 23.4% respectively, 
P<0.001) (figure 5).           
DISCUSSION
Accurate and early diagnosis of AMI in 
patients with related symptoms improves 
clinical outcome and prognosis. Moreover, 
determining the prognosis of AMI is es-
sential for triaging patients in the setting 
of limited resources in the ER.   
The use of plasma biomarkers has become 
central to the diagnosis and management 
of acute coronary syndromes and exclu-
sion of myocardial necrosis. (29) Specifi-
cally, the diagnostic value of troponin I or 
T (Tnl or TnT) elevation among patients 
with myocardial infarction (MI) is well es-
tablished. (30,31) Long-term mortality and 
morbidity following MI are largely deter-
mined by infarct size, and the extent of left 
ventricular (LV) dysfunction. (32) In our 
study, AMI patients who took longer to get 
to the ER from symptom onset, who were 
older and who were hypotensive at arrival 
were more likely to have a poor prognosis. 
Furthermore, other studies have shown 
that biomarkers are not just used for diag-
nosis but for prediction of prognosis. (33-
35) However, they only showed the utility 
of each biomarker for prognosis of specific 
disease.  
We believe that if these biomarkers are 
positive, the chance of involvement of 
the left main coronary artery, three-vessel 
coronary artery disease and left ventricu-
lar dysfunction will increase. Regard-
less of biomarker type, an increase in the 
number of positive biomarkers correlated 
with an increase in in-hospital mortal-
ity in our study. Eventually, this result will 
lead to higher in-hospital mortality. Given 
that the number of positive biomarkers 
is closely related to a higher risk of three 
coronary vessel disease, it may be useful in 
predicting the possibility of surgical treat-
ment, such as coronary artery bypass graft 
surgery (CABG), rather than coronary an-
giography alone. 
This was a retrospective study. Hence, there 
were some limitations. First, initial results 
of biomarkers were not able to predict in-
cidence and mortality of acute coronary 
vascular disease. Only data from patients 
with a final diagnosis of AMI, heart failure, 
and pulmonary embolism were analyzed 
and data from general patients complain-
ing of cardiovascular symptoms such as 
chest pain or shortness of breath were not 
able to be analyzed for risk stratification. 
Figure 3. Percentage of 3 vessel coronary 
disease in relation to number of positive 
POCT
Figure 4. Severity of left ventricular dys-
function in relation to number of positive 
POCT
Figure 5. In-hospital mortality rate in rela-
tion to number of positive POCT 
Table 1. Baseline characteristics of study patients
Characteristics Values
Age (mean ± SD, years) 58 ± 16
Male : Female (%) 859:477 (64.3% : 35.7%)
Initial symptoms
Chest pain, n (%) 972 (72.8)
Dyspnea, n (%) 289 (21.6)
Chest pain + dyspnea, n (%) 75 (5.6)
Final diagnosis
Acute myocardial infarction, n (%) 329 (24.6)
Congestive heart failure, n (%) 165 (12.4)
Pulmonary embolism, n (%) 17 (1.3)
Unstable angina, n (%) 156 (11.7)
Other Angina pectoris, n (%),  441 (33.0)
Arrhythmia, n (%) 27 (2.0)
Myocarditis, n (%) 14 (1.0)
Myopathy, n (%) 11 (0.8)
Aortic dissection or aneurysm, n (%) 17 (1.2)
Pulmonary disease, n (%) 53 (4.0)
Others, n (%) 106 (7.9)
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Second, due to the setting of in-hospital-
mortality as a prognostic index, assessing 
risk stratification between patients with 
minimal elevation of Tnl and patients with 
a normal range of Tnl was not possible. 
Third, we assumed initial elevation of D-
dimer in AMI patients was closely related 
to severe coronary vascular damage caused 
by a thrombus. In addition to that, visuali-
zation of thrombus formation by 2-D echo 
is required. Finally, a specific combination 
of biomarkers was not able to be identified. 
However, such information was not acces-
sible due to the retrospective study design. 
In spite of the retrospective study design, 
this study confirmed that multiple bio-
markers used in ER for differential diagno-
sis of acute cardiovascular disease also can 
be used as a prognostic risk stratification 
tool.
Our study identified the possibility of 
employing biomarkers from POCT as a 
prognostic tool. POCT is easy to use by the 
bedside and can be checked relatively ? in 
a short period of time. If the results from 
POCT is used to predict the prognosis of 
ACS patients, emergency physicians may 
approach patients with more caution. Pro-
spective studies are required to assess the 
utility of multiple biomarkers in the ER for 
acute cardiovascular disease’s incidence 
rate and for prediction of prognosis in pa-
tients with cardiovascular symptoms.
Table 2. Baseline characteristics of analyzed patients for death in hospital group and discharged alive group (N=1336)
Characteristics Death in hospital (n = 17) Discharged alive (n = 263) p-value
Age (mean ± SD, years) 72 ± 8 58 ± 13 < 0.001
Male (%) 5 /17 (29.41%) 53 /263 (20.15%) 0.360
Initial symptoms
Chest pain, n (%) 12 (70.6) 218 (82.9)
Short of breath, n (%) 2 (11.8) 23 (8.7)
Chest pain + SOB, n (%) 2 (11.8) 9 (3.4)
Epigastric & abdominal pain 1 (5.9) 12 (4.6)
General weakness or altered state 0 (0) 1 (0.4)
Symptom to presentation (hours) 9.5 (2.2-36.0) 2.9 (1.0-12.1) 0.033
Initial vital signs
Systolic blood pressure (mmHg) 103 ± 24 132 ± 26 < 0.001
Diastolic blood pressure (mmHg) 62 ± 27 80 ± 17 0.013
Pulse rate (beat/min) 77 ± 28 80 ± 19 0.689
Respiratory rate (breath/min) 21 ± 6 21 ± 3 0.893
MAP < 70 mmHg, n (%) 7 (41.2) 15 (5.7) < 0.001
Initial biomarkers  
CK-MB (ng/mL) 37.0 (1.5-74.5) 4.0 (1.0-18.0) 0.010
Myoglobin (ng/mL) 144 (93-500) 153 (65-456) 0.287
Tn-I (ng/mL) 16.0 (0-30) 0 (0-2.0) < 0.001
BNP (pg/mL) 532 (125-1180) 31 (5-215) < 0.001
D-dimer (ng/mL) 567 (259-1535) 119 (100-393) < 0.001
EF at 2D-echo (n=257) n=10 n=247 0.258
> 55%, n (%) 1 (10.0) 86 (34.8)
45-55%, n (%) 6 (60.0) 113 (45.7)
< 45%, n (%) 3 (30.0) 48 (19.4)
CAG finding
Left main involvement, n (%) 3 (17.6) 10 (3.8) 0.036
No. of involved coronary arteries
1 vessel, n (%) 2 (11.8) 127 (41.4) 0.005
2 vessels, n (%) 7 (41.2) 85 (32.3) 0.005
3 vessels, n (%) 8 (47.1) 51 (19.4) 0.005
BNP, brain natriuretic peptide; CAG, Coronary angiography; CK-MB, Creatine kinase MB; 2-D Echo, 2-dimensional echocardiogram; 
EF, Ejection fraction; MAP, Mean arterial pressure; SOB, Shortness of breath; TnI, troponin I.
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